Harmony Biosciences posted another quarter of rapid expansion, driven by accelerating demand for its flagship narcolepsy ...

In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.